Eribulin
Eribulin 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Breast Neoplasms。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
24 项
全球在招研究
10 项
已进入 III/IV 期
23 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- BioNTech SE
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- Sun Yat-sen University
- Memorial Sloan Kettering Cancer Center
- Sichuan Baili Pharmaceutical Co., Ltd.
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
中国、美国、Argentina、澳大利亚、比利时、Brazil、加拿大、Czechia、Georgia、德国、意大利、日本
正在招募患者的 Eribulin 研究
TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer
III 期招募中中国NCT07047365ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
III 期招募中美国Argentina澳大利亚比利时NCT07173751Adaptive Chemotherapy for the Treatment of Advanced Breast Cancer
III 期招募中中国NCT07088263A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
II 期招募中美国NCT06099769A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer
III 期招募中中国NCT06957886A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer
II 期招募中美国NCT05570253Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer
III 期招募中中国NCT06081959Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer
III 期招募中中国NCT06889688Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer
I 期 / II 期招募中中国NCT06942234Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer
III 期招募中中国NCT06255392Anlotinib-based Combination Therapy in Patients with Hormone Receptor-positive（HR+） Metastatic Breast Cancer(MBC) .
不适用招募中中国NCT06734533Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer
II 期招募中中国NCT06649331A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer
I 期 / II 期招募中中国NCT06202261A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors.
II 期招募中中国NCT06889610Scalp Cooling in MBC
II 期招募中美国NCT04986579Arsenous Acid for Refractory Triple-Negative Breast Cancer
II 期招募中中国NCT06678048ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
II 期招募中美国加拿大法国意大利NCT07007559JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
III 期招募中中国NCT06079983Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease
II 期招募中美国意大利瑞典英国NCT06875128LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer
II 期招募中中国NCT06387628YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer
III 期招募中中国NCT07461454A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)
III 期招募中美国加拿大法国德国NCT06263231DESTINY Breast Respond HER2-(Ultra)Low Europe
不适用招募中奥地利比利时丹麦法国NCT05945732A First-in-human of Multiplle Doses of BB-1705 in Subjects With Locally Advanced/Metastatic Solid Tumors
I 期招募中中国NCT05217693
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。